anti–pd-l1 plus targeted therapy in anaplastic thyroid carcinoma
Published 10 days ago • 241 plays • Length 20:42Download video MP4
Download video MP3
Similar videos
-
0:52
responses seen with anti-pd-1 antibody in anaplastic thyroid cancer cohort
-
12:16
anaplastic thyroid cancer treatment and survival outcomes
-
1:39
pembrolizumab/lenvatinib combo achieves promising responses in anaplastic thyroid cancer
-
33:16
advances in management of anaplastic thyroid cancer advances in targeted treatment kate newbold
-
1:04
targeted agents evolve in anaplastic, medullary thyroid cancer treatment paradigms
-
3:57
anti–pd-l1 therapy for locally advanced nsclc
-
1:03:08
anaplastic thyroid cancer with dr. nancy lee
-
3:52
systemic therapy in pd-l1–positive gastric cancer
-
5:45
immunotherapy for anaplastic thyroid carcinoma
-
7:37
combining immunotherapies: inhibiting the ctla-4 and pd-1 pathways
-
57:17
management of anaplastic thyroid cancer with dr cabanillas 144
-
2:00
reviving the anti-tumor response in dtc
-
1:21
dr. dadu on current treatment approaches in anaplastic thyroid cancer
-
2:12
phase 1 study of anti-pd-l1 durvalumab plus gefitinib in tki-naïve patients with egfr-mutant nsclc
-
1:00
dr. lee on combining anti-pd-l1 to standard of care for head and neck cancer
-
59:19
targeted therapies for advanced thyroid cancers with dr haugen 261
-
1:05
edward kim, md, on anti-pd-l1/pd-1 combination therapies in treatment of lung cancer
-
1:41
dual anti–ctla-4 and anti–pd-1 blockade in rare tumors (dart) swog s1609
-
2:19
combining ctla-4 agents with pd-1/pd-l1 agents in lung cancer